


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on MAY 30, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

RESPONSE TO NOTIFICATION OF
DEFECTIVE RESPONSE
Patent Application
Docket No. ARS-124

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson
Serial No. : 10/573,625
Filed : March 28, 2006
Conf. No. : 9024
For : Therapeutic Uses of Chemokine Variants

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:

A Transmittal Letter, along with the executed Declaration (37 CFR 1.63) for Utility Application Using an Application Data Sheet and Power of Attorney forms, a Submission of Sequence Listing Under 37 CFR §§1.821-1.825 providing the sequence listing in computer readable format and an Amendment Under 37 CFR §1.825(a) through (c) providing the sequence listing on paper, was submitted to the Patent Office on March 9, 2007 in response to a Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) dated February 21, 2007. A Notification of Defective Response dated May 2, 2007 was received from the Patent and Trademark Office, along with a Raw Sequence Listing Error Report indicating that that the organism at sequence identifier <213> in SEQ ID NOs: 2-5 is an "invalid response."

Attached with this Response is a replacement Submission of Sequence Listing Under 37 CFR §§ 1.821-1.825 and an Amendment Under 37 CFR §1.825(a) through (c).

The Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Telephone No.: (352) 375-8100
Facsimile No.: (352) 372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Submission of Sequence Listing Under 37 CFR §§1.821-1.825
Amendment Under 37 CFR §1.825(a) through (c)